Amendment No. 1 to Transition Agreement, dated December 31, 2020, by and between Arch Therapeutics, Inc. and Richard Davis

Contract Categories: Human Resources - Transition Agreements
EX-10.1 2 tm2114832d1_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1


  Arch Therapeutics, Inc.
235 Walnut Street, Suite 6
Framingham, MA 01702



May 3, 2021



Arch Therapeutics, Inc. (the “Company”) and Mr. Richard Davis agree to Amend the Transition and General Release Agreement executed as of December 31, 2020 between the parties, and Mr. Davis will serve as the Chief Financial Officer until May 10, 2021; the Transition End Date will occur on June 30, 2021; and as of July 1, 2021, the Post Executive Period will commence and continue through December 31, 2021.



/s/ Terrence W. Norchi   /s/ Richard E. Davis
Terrence W. Norchi, MD   Richard E. Davis
President and Chief Executive Officer   Chief Financial Officer